Molecular biology of mantle cell lymphoma: From profiling studies to new therapeutic strategies

Blood Reviews

Volumn 23, Issue 5, 2009, Pages 205-216

  Obrador Hevia, Antònia ^a   Mattos, Silvia Fernández de ^a   Villalonga, Priam ^a   Rodríguez, José ^a,b  

^a UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Genomic profiling; Mantle cell lymphoma; Therapeutic targets

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTIIDIOTYPIC ANTIBODY; BORTEZOMIB; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FLAVOPIRIDOL; FLUDARABINE; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; METHOTREXATE; MITOXANTRONE; PREDNISONE; PROTEASOME INHIBITOR; RAPAMYCIN; RETINOIC ACID; RITUXIMAB; ROSCOVITINE; TANESPIMYCIN; TEMSIROLIMUS; THALIDOMIDE; UNINDEXED DRUG; VINCRISTINE; VORINOSTAT; WORTMANNIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL CYCLE REGULATION; CELL SURVIVAL; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 14; CLINICAL TRIAL; COMPARATIVE GENOMIC HYBRIDIZATION; DNA DAMAGE; DOSE RESPONSE; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MANTLE CELL LYMPHOMA; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELL CYCLE; CYCLIN D1; DNA DAMAGE; ENZYME INHIBITORS; GENE EXPRESSION PROFILING; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOMA, MANTLE-CELL; PROTEIN KINASE INHIBITORS;

EID: 68349144124     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2009.03.001     Document Type: Article

References (141)

1. Andersen N.S., Jensen M.K., De Nully Brown P., and Geisler C.H. A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors. Eur J Cancer 38 3 (2002) 401-408
2. Bosch F., Lopez-Guillermo A., Campo E., Ribera J.M., Conde E., Piris M.A., et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 82 3 (1998) 567-575
3. Jaffe E.S., Harris N.L., Diebold J., and Muller-Hermelink H.K. World Health Organization Classification of lymphomas: a work in progress. Ann Oncol 9 Suppl. 5 (1998) S25-S30
4. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J., et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 13 2 (2000) 193-207
5. Banks P.M., Chan J., Cleary M.L., Delsol G., De Wolf-Peeters C., Gatter K., et al. Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 16 7 (1992) 637-640
6. Salar A., Juanpere N., Bellosillo B., Domingo-Domenech E., Espinet B., Seoane A., et al. Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study. Am J Surg Pathol 30 10 (2006) 1274-1280
7. Akiyama N., Tsuruta H., Sasaki H., Sakamoto H., Hamaguchi M., Ohmura Y., et al. Messenger RNA levels of five genes located at chromosome 11q13 in B-cell tumors with chromosome translocation t(11;14)(q13;q32). Cancer Res 54 2 (1994) 377-379
8. Jaffe E.S., Harris N.L., Diebold J., and Muller-Hermelink H.K. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues A progress report. Am J Clin Pathol 111 Suppl. 1 (1999) S8-12
9. Fu K., Weisenburger D.D., Greiner T.C., Dave S., Wright G., Rosenwald A., et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 106 13 (2005) 4315-4321
10. Rosenwald A., and Staudt L.M. Gene expression profiling of diffuse large B-cell lymphoma. Leuk Lymphoma 44 Suppl. 3 (2003) S41-47
11. Yatabe Y., Suzuki R., Tobinai K., Matsuno Y., Ichinohasama R., Okamoto M., et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood 95 7 (2000) 2253-2261
12. Bodrug S.E., Warner B.J., Bath M.L., Lindeman G.J., Harris A.W., and Adams J.M. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. Embo J 13 9 (1994) 2124-2130
13. Lovec H., Grzeschiczek A., Kowalski M.B., and Moroy T. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. Embo J 13 15 (1994) 3487-3495
14. Adams J.M., Harris A.W., Pinkert C.A., Corcoran L.M., Alexander W.S., Cory S., et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318 6046 (1985) 533-538
15. Gladden A.B., Woolery R., Aggarwal P., Wasik M.A., and Diehl J.A. Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene 25 7 (2006) 998-1007
16. Langdon W.Y., Harris A.W., and Cory S. Acceleration of B-lymphoid tumorigenesis in E mu-myc transgenic mice by v-H-ras and v-raf but not v-abl. Oncogene Res 4 4 (1989) 253-258
17. McDonnell T.J., Deane N., Platt F.M., Nunez G., Jaeger U., McKearn J.P., et al. Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57 1 (1989) 79-88
18. Rosenbaum H., Webb E., Adams J.M., Cory S., and Harris A.W. N-myc transgene promotes B lymphoid proliferation, elicits lymphomas and reveals cross-regulation with c-myc. Embo J 8 3 (1989) 749-755
19. Vaux D.L., Cory S., and Adams J.M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335 6189 (1988) 440-442
20. Bryant J., Pham L., Yoshimura L., Tamayo A., Ordonez N., and Ford R.J. Development of intermediate-grade (mantle cell) and low-grade (small lymphocytic and marginal zone) human non-Hodgkin's lymphomas xenotransplanted in severe combined immunodeficiency mouse models. Lab Invest 80 4 (2000) 557-573
21. M'Kacher R., Farace F., Bennaceur-Griscelli A., Violot D., Clausse B., Dossou J., et al. Blastoid mantle cell lymphoma: evidence for nonrandom cytogenetic abnormalities additional to t(11;14) and generation of a mouse model. Cancer Genet Cytogenet 143 1 (2003) 32-38
22. Wang M., Zhang L., Han X., Yang J., Qian J., Hong S., et al. A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. Clin Cancer Res 14 7 (2008) 2154-2160
23. Smith M.R., Joshi I., Jin F., and Al-Saleem T. Murine model for mantle cell lymphoma. Leukemia 20 5 (2006) 891-893
24. Ford R.J., Shen L., Lin-Lee Y.C., Pham L.V., Multani A., Zhou H.J., et al. Development of a murine model for blastoid variant mantle-cell lymphoma. Blood 109 11 (2007) 4899-4906
25. Allen J.E., Hough R.E., Goepel J.R., Bottomley S., Wilson G.A., Alcock H.E., et al. Identification of novel regions of amplification and deletion within mantle cell lymphoma DNA by comparative genomic hybridization. Br J Haematol 116 2 (2002) 291-298
26. Bea S., Ribas M., Hernandez J.M., Bosch F., Pinyol M., Hernandez L., et al. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 93 12 (1999) 4365-4374
27. Bentz M., Plesch A., Bullinger L., Stilgenbauer S., Ott G., Muller-Hermelink H.K., et al. T(11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia. Gene Chromosome Cancer 27 3 (2000) 285-294
28. Jarosova M., Papajik T., Holzerova M., Dusek L., Pikalova Z., Lakoma I., et al. High incidence of unbalanced chromosomal changes in mantle cell lymphoma detected by comparative genomic hybridization. Leuk Lymphoma 45 9 (2004) 1835-1846
29. Kohlhammer H., Schwaenen C., Wessendorf S., Holzmann K., Kestler H.A., Kienle D., et al. Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions. Blood 104 3 (2004) 795-801
30. Monni O., Oinonen R., Elonen E., Franssila K., Teerenhovi L., Joensuu H., et al. Gain of 3q and deletion of 11q22 are frequent aberrations in mantle cell lymphoma. Genes Chromosomes Cancer 21 4 (1998) 298-307
31. Salaverria I., Zettl A., Bea S., Moreno V., Valls J., Hartmann E., et al. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol 25 10 (2007) 1216-1222
32. Thelander E.F., Walsh S.H., Thorselius M., Laurell A., Landgren O., Larsson C., et al. Mantle cell lymphomas with clonal immunoglobulin V(H)3-21 gene rearrangements exhibit fewer genomic imbalances than mantle cell lymphomas utilizing other immunoglobulin V(H) genes. Mod Pathol 18 3 (2005) 331-339
33. de Leeuw R.J., Davies J.J., Rosenwald A., Bebb G., Gascoyne R.D., Dyer M.J., et al. Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. Hum Mol Genet 13 17 (2004) 1827-1837
34. Flordal Thelander E., Ichimura K., Collins V.P., Walsh S.H., Barbany G., Hagberg A., et al. Detailed assessment of copy number alterations revealing homozygous deletions in 1p and 13q in mantle cell lymphoma. Leuk Res 31 9 (2007) 1219-1230
35. Mestre-Escorihuela C., Rubio-Moscardo F., Richter J.A., Siebert R., Climent J., Fresquet V., et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood 109 1 (2007) 271-280
36. Rubio-Moscardo F., Climent J., Siebert R., Piris M.A., Martin-Subero J.I., Nielander I., et al. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 105 11 (2005) 4445-4454
37. Schraders M., Pfundt R., Straatman H.M., Janssen I.M., van Kessel A.G., Schoenmakers E.F., et al. Novel chromosomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridization. Blood 105 4 (2005) 1686-1693
38. Tagawa H., Karnan S., Suzuki R., Matsuo K., Zhang X., Ota A., et al. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 24 8 (2005) 1348-1358
39. Vater I, Wagner F, Kreuz M, Berger H, Martin-Subero JI, Pott C, et al. GeneChip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma. Br J Haematol 2008.
40. Bea S, Salaverria I, Armengol L, Pinyol M, Fernandez V, Hartmann EM, et al. Uniparental disomies, homozygous deletions, amplifications and target genes in mantle cell lymphoma revealed by integrative high-resolution whole genome profiling. Blood 2008.
41. Nielaender I., Martin-Subero J.I., Wagner F., Martinez-Climent J.A., and Siebert R. Partial uniparental disomy: a recurrent genetic mechanism alternative to chromosomal deletion in malignant lymphoma. Leukemia 20 5 (2006) 904-905
42. Blenk S., Engelmann J.C., Pinkert S., Weniger M., Schultz J., Rosenwald A., et al. Explorative data analysis of MCL reveals gene expression networks implicated in survival and prognosis supported by explorative CGH analysis. BMC Cancer 8 1 (2008) 106
43. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 6769 (2000) 503-511
44. Rosenwald A., Wright G., Wiestner A., Chan W.C., Connors J.M., Campo E., et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3 2 (2003) 185-197
45. Ek S., Hogerkorp C.M., Dictor M., Ehinger M., and Borrebaeck C.A. Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. Cancer Res 62 15 (2002) 4398-4405
46. Hofmann W.K., de Vos S., Tsukasaki K., Wachsman W., Pinkus G.S., Said J.W., et al. Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Blood 98 3 (2001) 787-794
47. Martinez N., Camacho F.I., Algara P., Rodriguez A., Dopazo A., Ruiz-Ballesteros E., et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res 63 23 (2003) 8226-8232
48. Rinaldi A., Kwee I., Taborelli M., Largo C., Uccella S., Martin V., et al. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol 132 3 (2006) 303-316
49. Korz C., Pscherer A., Benner A., Mertens D., Schaffner C., Leupolt E., et al. Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes. Blood 99 12 (2002) 4554-4561
50. Nagy B., Lundan T., Larramendy M.L., Aalto Y., Zhu Y., Niini T., et al. Abnormal expression of apoptosis-related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma. Br J Haematol 120 3 (2003) 434-441
51. Xerri L., Devilard E., Bouabdallah R., Hassoun J., Chaperot L., Birg F., et al. Quantitative analysis detects ubiquitous expression of apoptotic regulators in B cell non-Hodgkin's lymphomas. Leukemia 13 10 (1999) 1548-1553
52. Tracey L., Perez-Rosado A., Artiga M.J., Camacho F.I., Rodriguez A., Martinez N., et al. Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. J Pathol 206 2 (2005) 123-134
53. Ewen M.E., Sluss H.K., Sherr C.J., Matsushime H., Kato J., and Livingston D.M. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73 3 (1993) 487-497
54. Dreyling M.H., Bullinger L., Ott G., Stilgenbauer S., Muller-Hermelink H.K., Bentz M., et al. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. Cancer Res 57 20 (1997) 4608-4614
55. Gronbaek K., Nedergaard T., Andersen M.K., thor Straten P., Guldberg P., Moller P., et al. Concurrent disruption of cell cycle associated genes in mantle cell lymphoma: a genotypic and phenotypic study of cyclin D1, p16, p15, p53 and pRb. Leukemia 12 8 (1998) 1266-1271
56. Pinyol M., Cobo F., Bea S., Jares P., Nayach I., Fernandez P.L., et al. P16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 91 8 (1998) 2977-2984
57. Pinyol M., Hernandez L., Cazorla M., Balbin M., Jares P., Fernandez P.L., et al. Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood 89 1 (1997) 272-280
58. Bea S., Tort F., Pinyol M., Puig X., Hernandez L., Hernandez S., et al. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 61 6 (2001) 2409-2412
59. Hernandez L., Bea S., Pinyol M., Ott G., Katzenberger T., Rosenwald A., et al. CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. Cancer Res 65 6 (2005) 2199-2206
60. Pinyol M., Bea S., Pla L., Ribrag V., Bosq J., Rosenwald A., et al. Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis. Blood 109 12 (2007) 5422-5429
61. Camacho E., Hernandez L., Hernandez S., Tort F., Bellosillo B., Bea S., et al. ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. Blood 99 1 (2002) 238-244
62. Fernandez V., Hartmann E., Ott G., Campo E., and Rosenwald A. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 23 26 (2005) 6364-6369
63. Rummel M.J., de Vos S., Hoelzer D., Koeffler H.P., and Hofmann W.K. Altered apoptosis pathways in mantle cell lymphoma. Leuk Lymphoma 45 1 (2004) 49-54
64. Ghobrial I.M., McCormick D.J., Kaufmann S.H., Leontovich A.A., Loegering D.A., Dai N.T., et al. Proteomic analysis of mantle-cell lymphoma by protein microarray. Blood 105 9 (2005) 3722-3730
65. Pham L.V., Tamayo A.T., Yoshimura L.C., Lo P., and Ford R.J. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 171 1 (2003) 88-95
66. Rudelius M., Pittaluga S., Nishizuka S., Pham T.H., Fend F., Jaffe E.S., et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 108 5 (2006) 1668-1676
67. Rizzatti E.G., Falcao R.P., Panepucci R.A., Proto-Siqueira R., Anselmo-Lima W.T., Okamoto O.K., et al. Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways. Br J Haematol 130 4 (2005) 516-526
68. Dreyling M., Unterhalt M., Weigert O., and Hiddemann W. Therapy of mantle cell lymphoma. Internist (Berl) 48 4 (2007) 382-388
69. Fisher R.I. Mantle cell lymphoma: at last, some hope for successful innovative treatment strategies. J Clin Oncol 23 4 (2005) 657-658
70. Ghielmini M., Schmitz S.F., Burki K., Pichert G., Betticher D.C., Stupp R., et al. The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 11 Suppl. 1 (2000) 123-126
71. Dreyling M., Lenz G., Hoster E., Van Hoof A., Gisselbrecht C., Schmits R., et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 105 7 (2005) 2677-2684
72. Andersen N.S., Pedersen L., Elonen E., Johnson A., Kolstad A., Franssila K., et al. Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant. Eur J Haematol 71 2 (2003) 73-80
73. Khouri I., Saliba R.M., Okoroji G.J., Acholonu S., and Champlin R. Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first remission: the prognostic value of B2m and the tumor score. Cancer 98 (2003) 2630-2635
74. Maris M.B., Sandmaier B.M., Storer B.E., Chauncey T., Stuart M.J., Maziarz R.T., et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104 12 (2004) 3535-3542
75. Khouri I.F., Lee M.S., Saliba R.M., Jun G., Fayad L., Younes A., et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 21 23 (2003) 4407-4412
76. Neelapu S.S., Kwak L.W., Kobrin C.B., Reynolds C.W., Janik J.E., Dunleavy K., et al. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med 11 9 (2005) 986-991
77. Lawlor M.A., and Alessi D.R. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses?. J Cell Sci 114 Pt 16 (2001) 2903-2910
78. Testa J.R., and Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 98 20 (2001) 10983-10985
79. Dal Col J., Zancai P., Terrin L., Guidoboni M., Ponzoni M., Pavan A., et al. Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood 111 10 (2008) 5142-5151
80. Chiu M.I., Katz H., and Berlin V. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc Natl Acad Sci USA 91 26 (1994) 12574-12578
81. Neshat M.S., Mellinghoff I.K., Tran C., Stiles B., Thomas G., Petersen R., et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98 18 (2001) 10314-10319
82. Kawamata S., Sakaida H., Hori T., Maeda M., and Uchiyama T. The upregulation of p27Kip1 by rapamycin results in G1 arrest in exponentially growing T-cell lines. Blood 91 2 (1998) 561-569
83. Hashemolhosseini S., Nagamine Y., Morley S.J., Desrivieres S., Mercep L., and Ferrari S. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 273 23 (1998) 14424-14429
84. Peponi E., Drakos E., Reyes G., Leventaki V., Rassidakis G.Z., and Medeiros L.J. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol 169 6 (2006) 2171-2180
85. Hipp S., Ringshausen I., Oelsner M., Bogner C., Peschel C., and Decker T. Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells. Haematologica 90 10 (2005) 1433-1434
86. Yazbeck V.Y., Buglio D., Georgakis G.V., Li Y., Iwado E., Romaguera J.E., et al. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp Hematol 36 4 (2008) 443-450
87. Haritunians T., Mori A., O'Kelly J., Luong Q.T., Giles F.J., and Koeffler H.P. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 21 2 (2007) 333-339
88. Witzig T.E., Geyer S.M., Ghobrial I., Inwards D.J., Fonseca R., Kurtin P., et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23 23 (2005) 5347-5356
89. Yee K.W., Zeng Z., Konopleva M., Verstovsek S., Ravandi F., Ferrajoli A., et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 12 17 (2006) 5165-5173
90. Rizzieri D.A., Feldman E., Dipersio J.F., Gabrail N., Stock W., Strair R., et al. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 14 9 (2008) 2756-2762
91. Baeuerle P.A., and Baltimore D. NF-kappa B: ten years after. Cell 87 1 (1996) 13-20
92. Karin M., Cao Y., Greten F.R., and Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2 4 (2002) 301-310
93. Bottero V., Withoff S., and Verma I.M. NF-kappaB and the regulation of hematopoiesis. Cell Death Differ 13 5 (2006) 785-797
94. Roue G., Perez-Galan P., Lopez-Guerra M., Villamor N., Campo E., and Colomer D. Selective inhibition of IkappaB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level. J Immunol 178 3 (2007) 1923-1930
95. O'Connor O.A. Targeting histones and proteasomes: new strategies for the treatment of lymphoma. J Clin Oncol 23 26 (2005) 6429-6436
96. Chiarle R., Budel L.M., Skolnik J., Frizzera G., Chilosi M., Corato A., et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 95 2 (2000) 619-626
97. Perez-Galan P., Roue G., Villamor N., Montserrat E., Campo E., and Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 107 1 (2006) 257-264
98. Weigert O., Pastore A., Rieken M., Lang N., Hiddemann W., and Dreyling M. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia 21 3 (2007) 524-528
99. O'Connor O.A., Wright J., Moskowitz C., Muzzy J., MacGregor-Cortelli B., Stubblefield M., et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23 4 (2005) 676-684
100. Goy A., Younes A., McLaughlin P., Pro B., Romaguera J.E., Hagemeister F., et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23 4 (2005) 667-675
101. Fisher R.I., Bernstein S.H., Kahl B.S., Djulbegovic B., Robertson M.J., de Vos S., et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24 30 (2006) 4867-4874
102. Belch A., Kouroukis C.T., Crump M., Sehn L., Gascoyne R.D., Klasa R., et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 18 1 (2007) 116-121
103. Perez-Galan P., Roue G., Villamor N., Campo E., and Colomer D. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 109 10 (2007) 4441-4449
104. Wang M., Han X.H., Zhang L., Yang J., Qian J.F., Shi Y.K., et al. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia 22 1 (2008) 179-185
105. Jones L.K., and Saha V. Chromatin modification, leukaemia and implications for therapy. Br J Haematol 118 3 (2002) 714-727
106. Heider U., Kaiser M., Sterz J., Zavrski I., Jakob C., Fleissner C., et al. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Eur J Haematol 76 1 (2006) 42-50
107. Sakajiri S., Kumagai T., Kawamata N., Saitoh T., Said J.W., and Koeffler H.P. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 33 1 (2005) 53-61
108. Kawamata N., Chen J., and Koeffler H.P. Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood 110 7 (2007) 2667-2673
109. O'Connor O.A., Heaney M.L., Schwartz L., Richardson S., Willim R., MacGregor-Cortelli B., et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24 1 (2006) 166-173
110. Heider U., von Metzler I., Kaiser M., Rosche M., Sterz J., Rotzer S., et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol 80 2 (2008) 133-142
111. Morimoto R.I., and Santoro M.G. Stress-inducible responses and heat shock proteins: new pharmacologic targets for cytoprotection. Nat Biotechnol 16 9 (1998) 833-838
112. Georgakis G.V., Li Y., and Younes A. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9. Br J Haematol 135 1 (2006) 68-71
113. Sherr C.J. Mammalian G1 cyclins. Cell 73 6 (1993) 1059-1065
114. Sherr C.J. G1 phase progression: cycling on cue. Cell 79 4 (1994) 551-555
115. Senderowicz A.M., and Sausville E.A. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 92 5 (2000) 376-387
116. Kouroukis C.T., Belch A., Crump M., Eisenhauer E., Gascoyne R.D., Meyer R., et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21 9 (2003) 1740-1745
117. Lacrima K., Valentini A., Lambertini C., Taborelli M., Rinaldi A., Zucca E., et al. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Ann Oncol 16 7 (2005) 1169-1176
118. Park I.W., Reddy M.V., Reddy E.P., and Groopman J.E. Evaluation of novel cell cycle inhibitors in mantle cell lymphoma. Oncogene 26 38 (2007) 5635-5642
119. Ramanarayanan J., Hernandez-Ilizaliturri F.J., Chanan-Khan A., and Czuczman M.S. Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab. Br J Haematol 127 5 (2004) 519-530
120. O'Brien S.M., Cunningham C.C., Golenkov A.K., Turkina A.G., Novick S.C., and Rai K.R. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 23 30 (2005) 7697-7702
121. Tucker C.A., Kapanen A.I., Chikh G., Hoffman B.G., Kyle A.H., Wilson I.M., et al. Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-kappaB, p53, bax, and p27 levels. Mol Cancer Ther 7 4 (2008) 749-758
122. Paoluzzi L., Gonen M., Gardner J.R., Mastrella J., Yang D., Holmlund J., et al. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood 111 11 (2008) 5350-5358
123. Paoluzzi L., Gonen M., Bhagat G., Furman R.R., Gardner J.R., Scotto L., et al. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 112 7 (2008) 2906-2916
124. Henson E.S., Johnston J.B., and Gibson S.B. The role of TRAIL death receptors in the treatment of hematological malignancies. Leuk Lymphoma 49 1 (2008) 27-35
125. Eucker J., Sterz J., Krebbel H., Zavrski I., Kaiser M., Zang C., et al. Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma. Anticancer Drugs 17 7 (2006) 763-769
126. Damaj G., Lefrere F., Delarue R., Varet B., Furman R., and Hermine O. Thalidomide therapy induces response in relapsed mantle cell lymphoma. Leukemia 17 9 (2003) 1914-1915
127. Kaufmann H., Raderer M., Wohrer S., Puspok A., Bankier A., Zielinski C., et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 104 8 (2004) 2269-2271
128. Langenfeld J., Kiyokawa H., Sekula D., Boyle J., and Dmitrovsky E. Posttranslational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanism. Proc Natl Acad Sci USA 94 22 (1997) 12070-12074
129. Guidoboni M., Zancai P., Cariati R., Rizzo S., Dal Col J., Pavan A., et al. Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma. Cancer Res 65 2 (2005) 587-595
130. Haluska P., Dy G.K., and Adjei A.A. Farnesyl transferase inhibitors as anticancer agents. Eur J Cancer 38 13 (2002) 1685-1700
131. David E., Sun S.Y., Waller E.K., Chen J., Khuri F.R., and Lonial S. The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. Blood 106 13 (2005) 4322-4329
132. Rolland D., Camara-Clayette V., Barbarat A., Salles G., Coiffier B., Ribrag V., et al. Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma. Cancer Chemother Pharmacol 61 5 (2008) 855-863
133. Su T.T., Guo B., Kawakami Y., Sommer K., Chae K., Humphries L.A., et al. PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol 3 8 (2002) 780-786
134. Decouvelaere A.V., Morschhauser F., Buob D., Copin M.C., and Dumontet C. Heterogeneity of protein kinase C beta(2) expression in lymphoid malignancies. Histopathology 50 5 (2007) 561-566
135. Graff J.R., McNulty A.M., Hanna K.R., Konicek B.W., Lynch R.L., Bailey S.N., et al. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65 16 (2005) 7462-7469
136. Morschhauser F., Seymour J.F., Kluin-Nelemans H.C., Grigg A., Wolf M., Pfreundschuh M., et al. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol 19 2 (2008) 247-253
137. Lepelletier Y., Camara-Clayette V., Jin H., Hermant A., Coulon S., Dussiot M., et al. Prevention of mantle lymphoma tumor establishment by routing transferrin receptor toward lysosomal compartments. Cancer Res 67 3 (2007) 1145-1154
138. Ek S., Ortega E., and Borrebaeck C.A. Transcriptional profiling and assessment of cell lines as in vitro models for mantle cell lymphoma. Leuk Res 29 2 (2005) 205-213
139. Ek S., Andreasson U., Hober S., Kampf C., Ponten F., Uhlen M., et al. From gene expression analysis to tissue microarrays: a rational approach to identify therapeutic and diagnostic targets in lymphoid malignancies. Mol Cell Proteomics 5 6 (2006) 1072-1081
140. Ortega-Paino E., Fransson J., Ek S., and Borrebaeck C.A. Functionally associated targets in mantle cell lymphoma as defined by DNA microarrays and RNA interference. Blood 111 3 (2008) 1617-1624
141. Ek S., Bjorck E., Hogerkorp C.M., Nordenskjold M., Porwit-MacDonald A., and Borrebaeck C.A. Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival. Int J Cancer 118 8 (2006) 2092-2097